Bio-Rad Laboratories (BIO) to Release Earnings on Wednesday

Key Points

• Bio-Rad Laboratories (NYSE:BIO) is set to announce its Q3 2025 earnings on Wednesday, October 29th, with analysts predicting earnings of $2.25 per share and $651.30 million in revenue.
• The company's previous quarter saw an earnings per share (EPS) of $2.61, exceeding expectations by $0.68, with revenue up 2.1% year-over-year.
• Bio-Rad shares opened at $331.31, showing a market cap of $8.97 billion and a consensus rating of "Hold" based on recent analyst assessments.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) is expected to announce its Q3 2025 results after the market closes on Wednesday, October 29th. Analysts expect the company to announce earnings of $2.25 per share and revenue of $651.3020 million for the quarter. Bio-Rad Laboratories has set its FY 2025 guidance at EPS.Parties are encouraged to explore the company's upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 5:00 PM ET.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.93 by $0.68. Bio-Rad Laboratories had a return on equity of 4.01% and a net margin of 12.50%.The firm had revenue of $651.60 million for the quarter, compared to analyst estimates of $614.82 million. During the same period in the previous year, the firm earned $3.11 earnings per share. The company's revenue was up 2.1% compared to the same quarter last year. On average, analysts expect Bio-Rad Laboratories to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

Bio-Rad Laboratories Price Performance

Shares of BIO opened at $331.31 on Wednesday. Bio-Rad Laboratories has a 52-week low of $211.43 and a 52-week high of $387.99. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.67 and a current ratio of 5.12. The business's 50 day moving average price is $292.27 and its two-hundred day moving average price is $259.99. The firm has a market cap of $8.97 billion, a PE ratio of 28.24 and a beta of 0.97.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Zacks Research raised Bio-Rad Laboratories from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 26th. Wall Street Zen lowered Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, August 22nd. Weiss Ratings reissued a "sell (d+)" rating on shares of Bio-Rad Laboratories in a research report on Tuesday, October 14th. Royal Bank Of Canada upped their price objective on Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an "outperform" rating in a research note on Friday, August 1st. Finally, Wells Fargo & Company upped their price objective on Bio-Rad Laboratories from $245.00 to $265.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Bio-Rad Laboratories presently has a consensus rating of "Hold" and an average price target of $333.50.

Hedge Funds Weigh In On Bio-Rad Laboratories

Several institutional investors and hedge funds have recently bought and sold shares of BIO. Scopia Capital Management LP bought a new position in Bio-Rad Laboratories during the 2nd quarter worth approximately $22,862,000. Man Group plc grew its position in Bio-Rad Laboratories by 1,096.0% during the 2nd quarter. Man Group plc now owns 80,288 shares of the medical research company's stock worth $19,375,000 after acquiring an additional 73,575 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Bio-Rad Laboratories by 45.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 105,006 shares of the medical research company's stock worth $25,575,000 after acquiring an additional 32,874 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of Bio-Rad Laboratories in the 2nd quarter worth approximately $5,786,000. Finally, Brevan Howard Capital Management LP bought a new stake in shares of Bio-Rad Laboratories in the 2nd quarter worth approximately $5,264,000. 65.24% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.